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Efficacy of Femoral Vascular Closure
Devices in Patients Treated with
Anticoagulant, Abciximab or
Thrombolytics during Percutaneous
Endovascular Procedures
Objective: This study assessed the outcomes of using vascular closure
devices following percutaneous transfemoral endovascular procedures in the
patients who were treated with heparin, abciximab or thrombolytics (urokinase or
t-PA) during the procedures. 
Materials and Methods: From March 28, 2003 to August 31, 2004, we con-
ducted a prospective and randomized study in which 1,676 cases of 1,180
patients were treated with one of the two different closure devices (the collagen
plug device was Angio-Seal
TM; the suture-mediated closure device was The
Closer S
TM) at the femoral access site after instituting percutaneous endovascular
procedures. Among the 1,676 cases, 108 cases (the drug group) were treated
with heparin only (n = 94), thrombolytics only (n = 10), heparin and thrombolytics
(n = 3), or abciximab and thrombolytics (n = 1) during the procedures; 1,568
cases (the no-drug group) were treated without any medication. We compared
the efficacy and complications between the two groups. Of the drug group, 42
cases underwent arterial closures with the collagen plug devices and 66 cases
underwent arterial closures with the suture-mediated closure devices. We also
compared the efficacy and complications between these two groups.
Results: The immediate hemostasis rates were 92.9% (1,456/1,568) in the no-
drug group and 91.7% (99/108) in the drug group. Early complications occurred in
four cases of the drug group. These included two episodes of rebleeding with using
the Closer S, which required manual compression for at least 10 minutes, and two
episodes of minor oozing with using one Angio-Seal and one Closer S, which
required two hours of additional bed rest. There was no late complication. So, the
total success rates were 90.8% (1,423/1,568) in the no-drug group and 88.0%
(95/108) in the drug group. These results were not significantly different between
the two groups (p = 0.34). In the drug group, the difference of the successful hemo-
stasis rate between the collagen plug devices and the suture-mediated devices was
also not statistically significant (92.9% vs. 84.8%, respectively; p = 0.21). 
Conclusion: Arterial closure of the femoral access site with using vascular clo-
sure devices is both safe and effective, even in the patients who received
heparin, abciximab or thrombolytics. 
he femoral artery is the most frequent access site that is targeted for
percutaneous endovascular procedures. Arterial puncture sites after
catheterization tend to be associated with bleeding, hematoma, pseudoa-
neurysm and a variety of other complications. These complications may also be associ-
ated with significant patient discomfort, an increased hospital stay, blood transfusion
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e-mail: swchoo@smc.samsung.co.kr Tand sometimes vascular surgery (1). Up to 10% of these
patients complain of significant local complications, includ-
ing hematoma and pseudoaneurysms. In 1 2% of such
cases, these complications require vascular surgical
intervention or transfusion (2 4). The rates of these
complications may depend on the operator’s experience,
the type of intervention attempted, the introducer size and
primarily, on the duration of the manual compression (5). 
Therefore, several closure devices have been developed
to facilitate hemostasis, allow early ambulation and
discharge, and to ameliorate patient discomfort (1). One of
these devices utilizes collagen for the management of
access site closure (VasoSeal, Angio-Seal, Duett).
Alternatively, a percutaneous suturing device (Prostar,
Techstar, Closer) allows for surgical closure of the femoral
artery with very little trauma being incurred by the overly-
ing tissue (4, 6, 7). In some reports, the suture-based
closure device has been demonstrated to be both safe and
effective for the induction of immediate hemostasis and
early ambulation, and there was no concomitant increase
in the risk of bleeding complications (8, 9). Koreny et al.
(10) suggested that the arterial puncture closing devices
appeared to be effective in terms of reducing the time that
is necessary for hemostasis, but complications such as
hematoma and pseudoaneurysm formation occurred more
often than for standard manual compression, as based on
the meta-analysis of 30 randomized trials. 
Anyway, the vascular closure devices have been
frequently used for the patients who have recently
undergone peripheral vascular diagnostic and therapeutic
procedures (11, 12). These devices are particularly used for
patients who have either been heparinized or heavily
anticoagulated (13). An increase in the number of available
diagnostic and therapeutic interventional procedures, as
well as the use of new antiplatelet agents during
angioplasty, has coincided with an upswing in the
frequency with which these devices are used (11). These
devices share common goals of achieving prompt hemosta-
sis, even in a setting of systemic anticoagulation, allowing
for earlier ambulation and helping to prevent groin compli-
cations (14). 
In this study, we assessed the safety and efficacy of using
two closure devices, the collagen plug device (Angio-
Seal
TM; Daig Corporation, Minnetonka, MN) and the
suture-mediated device (The Closer S
TM; Abbott
Corporation, Redwood City, CA), after performing
percutaneous endovascular procedures in patients who
received heparin, abciximab or thrombolytics (urokinase
or t-PA) during the procedures. We also compared the
outcomes of the two vascular closure devices. 
MATERIALS AND METHODS
The choice of methods that were used to obtain hemosta-
sis, including manual compression or vascular closure
devices, was left to the discretion of patients after they
were given an explanation about the efficacy and side
effects of the vascular closure devices. The use of the
vascular closure devices was attempted in all patients if
they gave their written informed consents prior to the
procedures. The exclusion criteria for the study included
difficulty in puncturing the artery, severe peripheral
vascular disease, marked obesity, an age < 15 years and an
arterial sheath < 4 Fr or > 8 Fr. 
From March 28, 2003 to August 31, 2004, 1,180 patients
who underwent 1,676 percutaneous transfemoral endovas-
cular procedures at the Samsung Medical Center (SMC)
were eligible for our study. These patients were random-
ized into two groups that received either the collagen plug
device (Angio-Seal
TM) or the suture-mediated device (the
Closer S
TM). Of our 1,676 cases, 961 cases were treated
with Angio-Seal and 715 cases were treated with the
Closer S. The interventional radiologists and neuroradiolo-
gists at SMC had experience with 322 cases of Angio-Seal
and 97 cases of Closer S at the beginning of this study.
The placement of either type of closure device was
performed using the manufacturer’s recommended
technique. Ambulation was normally initiated two hours
after the placement of the relevant arterial closure device.
The demographic and clinical outcome data were prospec-
tively collected using a standardized “procedural data
sheet” and the data was recorded on the day on which the
procedure was performed, 24 hours afterward and at one
month, or at the time when the complications were noted.
The procedural data included the type of intervention, the
procedure data, the sheath size, the procedure-related drug
dose and the number of previous punctures. Major or minor
complications, as well as the time of events, were also
recorded. In all instances, further anticoagulation or use of
antiplatelet agents was decided upon by a consensus of the
interventional radiologists and the attending physicians. 
In 108 cases (100 patients) of the 1,676 cases, heparin,
thrombolytics or abciximab was administered intra-arteri-
ally or intravenously during the procedures. These 108
cases (the drug group) were then divided into the two
groups based on the type of closure devices used and the
drugs that were administered. We analyzed the immediate
successful hemostasis, complications and the total success
rates of these groups, and these cases were then compared
with the other 1,568 cases (the no-drug group) in which no
anticoagulant, thrombolytic or antiplatelet drug was used. 
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hours) or late (within 1 month). The minor complications
included any rebleeding or oozing from the puncture site
that proved to be controllable by manual compression, as
well as infections that were treatable with oral antibiotics.
The major complications were also assessed. These
included the need for vascular surgery, hemorrhage requir-
ing transfusion, a pseudoaneurysm or arteriovenous fistula,
arterial occlusion or distal arterial embolism, and infections
that were treatable only by the administration of IV antibi-
otics or debridement. 
Immediate hemostasis was defined as achieving hemosta-
sis after the deployment of the device, with or without
applying three minutes or less of manual compression.
Total success was defined as immediate hemostasis with no
complications. 
The data are expressed as means value  standard
deviation, unless otherwise indicated. Comparative
analyses were carried out with using standard chi-square
tests between each of the closure device groups, as well as
between the patient groups based on the drugs that were
administered. Fischer’s exact test was used if the expected
cell count for a 2 2 table was < 5. The two-tailed unpaired
Student t test was used to analyze continuous variables.
These comparisons were performed using the SPSS version
11.0 software package (SPSS Inc., Chicago, IL), and a p
value of  0.05 was considered to be significant. 
RESULTS
Of the 1,676 cases in the baseline study, 961 cases were
closed with using the Angio-Seal and 715 cases were
closed with using the Closer S. Table 1 displays the
baseline outcomes of the two groups, according to the
vascular closure devices that were used. Immediate
hemostasis was achieved in 95.2% of the cases treated
with the Angio-Seal and in 89.5% of the cases treated with
the Closer S (p < 0.001). Total success was achieved in
92.6% of the cases with using of the Angio-Seal and in
87.8% of the cases with using the Closer S (p < 0.01).
There were no statistically significant differences between
the two groups with regard to early or late complications. 
Of the 1,676 cases, 108 cases (100 patients) were treated
with heparin only (n = 94), thrombolytics only (n = 10),
combined heparin and thrombolytics (n = 3), or combined
abciximab and thrombolytics (n = 1) during the
procedures. The mean dose of heparin was 4,238 1,287.6
units, the mean dose of urokinase was 241,667 66,458
units, the mean dose of intravenous and/or intraarterial
tissue plasminogen activator (t-PA) was 32.3 16.6 mg
and the mean dose of abciximab was 5 mg. 
These 108 cases underwent a variety of procedures
including 10 (9.3%) diagnostic transfemoral carotid
angiographies (TFCA) and 98 (90.7%) interventional
procedures. The interventional procedures included 51
(47.2%) embolizations of intracranial aneurysms, 15
(13.9%) intra-arterial thrombolysis procedures for stroke
patients, 15 (13.9%) intracranial stent placements, eight
(7.4%) iliac stent placements, three (2.8%) intracranial
angioplasties, two (1.9%) balloon occlusions of giant
carotid aneurysms, two (1.9%) peripheral subintimal
angioplasties, one (0.9%) embolization of a dural arteri-
ovenous malformation (AVM), and one (0.9%) renal stent
placement.
Of these 108 cases, the Angio-Seals were used in 42
cases (the Angio-Seal group), and the Closer S was used in
66 cases (the Closer S group). There was no difference
between the groups according the vascular closure devices
in terms of the demographic findings, the risk factors and
the coagulation profiles (Table 2). Immediate hemostasis
was achieved in 95.2% of the Angio-Seal group and in
89.4% of the Closer S group. Total success was achieved in
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Table 2. Comparison of the Demographic Findings, Risk
Factors, and Coagulation Profiles in the Drug Group 
Angio-Seal Closer  S 
(n = 42) (n = 66)
p
Age 54.5 11.1 53 15 0.14
Men 29 (69%)0. 43 (65.2%) 0.68
Diabetes mellitus 09 (21.4%) 17 (25.8%) 0.61
Hypertension 11 (26.2%) 23 (34.8%) 0.35
Cigarette smoking 16 (38.1%) 18 (27.3%) 0.24
Multiple punctures 12 (28.6%) 11 (16.7%) 0.14
Platelet count before 
procedure
205.3 60.2 217 62.6 0.35
Prothrombin time 
before procedure
1.01 0.14 1.10 0.27 0.06
Systemic anticoagulation 
after procedure
16 (38.1%) 25 (37.9) 0.98
Table 1. Baseline Outcomes* 
Angio-Seal Closer  S 
(n = 961) (n = 715)
p
Immediate hemostasis 
915 (95.2%) 640 (89.5%) < 0.001
success
Immediate hemostasis 
46 (4.8%) 75 (10.5%) < 0.001
failure
Total cx. 25 (2.6%) 12 (1.7%)0 0.20
Early cx. 19 (2.0%) 9 (1.3%) 0.26
Late cx. 06 (0.6%) 3 (0.4%) 0.57
Total success 890 (92.6%) 628 (87.8%)0 < 0.01
* In press 92.9% of the Angio-Seal group and in 84.8% of the Closer
S group. Early complications occurred in four patients.
These included two episodes of active rebleeding that
required manual compression for at least 10 minutes (2 in
the Closer S group), and two episodes of minor oozing that
required prolonged strict bed rest for at least an additional
two hours (1 in the Angio-Seal group and 1 in the Closer S
group). There was no late complication. In the drug group,
the successful hemostasis rate was higher for the collagen
plug devices than for the suture-mediated devices;
however, the difference was not statistically significant
(Table 3). Forty-one patients (38%) in the drug group
received systemic anticoagulation therapy after the
procedures.
All of the cases that exhibited early minor complications
were the heparin-only cases. The mean dose of heparin
that was administered in these four cases was 3,750 500
units, while the mean heparin dose in all the heparin-only
cases was 4,238 1,287.6 units. The 6-F arterial sheath
was used for three of these cases, and the 8 F was used for
one of the four cases in which complications occurred. Out
of the total 108 cases, the 5-F arterial sheath was used in
three cases (2.8%), the 6-F was used in 87 cases (80.6%),
the 7 F was used in three cases (2.8%), and the 8 F was
used in 15 cases (13.9%). Among the four patients with
minor complications, only one patient received systemic
anticoagulation after the procedure. We determined that
there was no association between the complications and
the heparin dose, the history of multiple punctures, the
coagulation profile and the systemic coagulation that was
used after the procedures in the drug group (Table 4).  
Both the no-drug and drug groups showed no significant
differences in the demographic findings and the risk
factors. However, for the drug group, the coagulation
profile was better than that for the no-drug group 
(p < 0.01) (Table 5). 
Immediate hemostasis was achieved in 92.9% of the no-
drug group and in 91.7% of the drug group. Total success
was achieved in 90.8% of the no-drug group and in 88.0%
of the drug group. There was no statistically significant
differences between these two groups (p = 0.34). Although
the early complication rate tended to be higher in the cases
that were administered with drugs, this difference was not
statistically significant (p = 0.10) (Table 6). 
DISCUSSION
The management of femoral artery access sites following
Kim et al.
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Table 3. Results in the Drug Group between the Two Closure
Devices
Angio-Seal Closer 
(n = 42) (n = 66)
p
Immediate hemostasis 
success
40 (95.2%) 59 (89.4%) 0.28
Immediate hemostasis 
failure
2 (4.8%) 7 (10.6%) 0.28
Early complication 1 (2.4%) 3 (4.5%)0 0.56
Late complication 0 0
Total success 39 (92.9%) 56 (84.8%) 0.21
Table 4. Comparison of the Cases with and without
Complications in the Drug Group 
No complication  Complication 
(n = 104) (n = 4)
p
Heparin dose (IU) 4,238 1,287.6 3,750 500 0.47
Multiple punctures 22 (21.2%) 1 (25.0%) 0.85
Platelet count before 
procedure
213.4 62.5 183.5 21.7 0.34
Prothrombin time 
before procedure
1.07 0.23 1.13 0.25 0.60
Systemic anticoagulation 
after procedure
40 (38.5%) 1 (25.0%) 0.59
Table 5. Comparison of the Demographic Findings and the
Coagulation Profile between the No-drug and Drug
Groups 
No-drug group Drug group
(n = 1,568) (n = 108)
p
Age 55.5 12.9 53 14 0.14
Men 1,090 (69.5%) 72 (66.7%) 0.54
Diabetes mellitus 379 (24.2%) 26 (24.1%) 0.98
Hypertension 371 (23.7%) 34 (31.5%) 0.07
Cigarette smoking 376 (24.0%) 34 (31.5%) 0.08
Platelet count before 
procedure
153.8 99.9 212.3 61.6 < 0.001
Prothrombin time 
before procedure
1.12 0.18 1.07 0.23 < 0.01
Table 6. Comparison of the Results between the No-drug
and Drug Groups 
No-drug group Drug group
(n = 1,568) (n = 108)
p
Immediate hemostasis 
success
1,456 (92.9%) 99 (91.7%) 0.64
Immediate hemostasis 
failure
,112 (7.1%) 9 (8.3%) 0.64
Early complication
,0
24 (1.5%) 4 (3.7%) 0.10
Late complication
,00
9 (0.6%) 0 0.55
Total success 1,423 (90.8%) 95 (88.0%) 0.34percutaneous intervention continues to be an important
aspect of diagnostic and therapeutic interventions.
Inducing adequate hemostasis must be done safely, and
this has traditionally been performed by manual compres-
sion or by using clamp-like compression devices (15 17).
Multiple variables have been associated with the
incidence of access-site complications in the patients who
have undergone percutaneous vascular interventions; these
variables include advanced age, diabetes, hypertension and
cigarette smoking (18). In addition, many studies have
suggested that concomitant anticoagulation or antiplatelet
therapy tends to increase the risks of complication in the
vascular access sites when only manual compression is
used (3, 19 23). 
A few studies have recently suggested that vascular
closure devices are both safe and effective for the manage-
ment of arterial access sites in the patients who receive
anticoagulant or antiplatelet therapy, as compared with
manual compression (14, 20). Applegate et al. (24) have
reported a major vascular complication rate of 0.9% for
the combined closure-device group and 1.3% for the
manual-pressure group in the patients who received
glycoprotein IIb/IIIa inhibitor therapy. Duffin et al. (25)
have suggested that routine abciximab use by itself was not
associated with vascular complications. Sesana et al. (26)
have recently reported a vascular complication rate of
2.5% for the patients treated with the Angio-Seal device,
and a rate of 3.4% for the patients who were treated with
the Prostar device; these rates closely approximated the
rates that we have reported here. These investigators also
concluded that the use of the glycoprotein IIb/IIIa antago-
nist, abciximab, was not associated with an increased risk
of vascular complications. The principal finding of our
study is that femoral arterial closures can be performed
both safely and effectively with the currently available
vascular closure devices in the patients who received
heparin, thrombolytics or abciximab during their
procedures. 
The reported success rates for the collagen plug and
suture-mediated closure devices have ranged from 90% to
100% (8, 27). In our baseline study, immediate hemostasis
was achieved in 95.2% of the 961 cases using the Angio-
Seal, and in 89.5% of the 715 cases using the Closer S (p <
0.001); total success was achieved in 92.6% of the cases
using the Angio-Seal, and in 87.8% of the cases using the
Closer S (p < 0.01). Thus, the use of the Angio-Seal
appeared to be slightly more effective than that of the
Closer S, with regard to inducing hemostasis at the femoral
access site. 
The immediate hemostasis rates were 92.9%
(1,456/1,568) in the no-drug group and 91.7% (99/108) in
the drug group. The total success rates were 90.8%
(1,423/1,568) in the no-drug group and 88.0% (95/108) in
the drug group. However, no statistically significant differ-
ences were determined to exist between these two groups
according to the medications they received. The early
complication rates tended to be higher when the patients
had received the medications, but this difference was also
not significant statistically. The higher dose of the medica-
tions, a history of multiple punctures, the coagulation
function and further systemic anticoagulation after the
procedures appeared to have no effect on the complication
rates, based on our experiences.
There are two limitations of our study. First, our data
showed a statistically significant difference in the coagula-
tion profile between the no-drug group and the drug
group. Among the no-drug group (1,568 cases), 808
(51.5%) cases with liver cirrhosis had undergone trans-
arterial chemoembolization for the treatment of hepatic
tumors, and these patients had impaired hepatic function.
Moreover, stricter indications for the procedures were
applied to the drug group. These factors may have
contributed to these unexpected results. In our supplemen-
tary study on the patients with early or late complications,
33.3% (22/33) of the no-drug group and none of the
patients of the drug group showed an abnormal platelet
count (p < 0.30). Further, all the patients with early or late
complications showed a normal prothrombin time before
the procedures. So, we considered that our results were
not influenced by these differences. Second, our study is
limited by the relatively small size of the drug group;
heparin, glycoprotein IIb/IIIa inhibitor or thrombolytics
was administered to only 6.4% of the total 1,656 cases.
For example, we described that the immediate hemostasis
and total success rates were not statistically different
between the two closure device groups in the drug group.
Indeed, the small sample size for the drug group
contributed to these varying results, as compared to the
baseline outcomes. A larger comparative study that
includes more patients treated with drugs during the
procedures is needed.
In conclusion, the use of anticoagulants, antiplatelet
agents or thrombolytics during the procedures does not
significantly affect the immediate/total success and the
complication rates, and these findings are regardless of the
types of vascular closure devices that are used. Therefore,
we can conclude that arterial closure of femoral access sites
using vascular closure devices constitutes a safe and
effective therapeutic treatment, even for the patients who
receive anticoagulant, abciximab, or thrombolytics during
the procedures. 
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